
rafal_olechowski
Alvotech (NASDAQ:ALVO) and British pharmaceutical company Advanz Pharma announced Wednesday an agreement to expand their commercial collaboration to market three additional biosimilar candidates in Europe.
Biosimilars for the anti-inflammatory agent Ilaris and multiple sclerosis therapy Kesimpta, both marketed by Novartis (